期刊
FRONTIERS IN PHYSIOLOGY
卷 3, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphys.2012.00012
关键词
TGF-beta; TSP-1; beta 6 integrin; fibronectin; local bioavailability; liver disease
类别
资金
- U.S. National Institutes of Health [R01 DK074538]
- Byotai Taisha Research Foundation
- Uehara Memorial Foundation, Japan
The cytokine transforming growth factor-beta (TGF-beta) plays a pivotal role in a diverse range of cellular responses, including cell proliferation, apoptosis, differentiation, migration, adhesion, angiogenesis, stimulation of extracellular matrix (ECM) synthesis, and downregulation of ECM degradation. TGF-beta and its receptors are ubiquitously expressed by most cell types and tissues in vivo. In intact adult tissues and organs, TGF-beta is secreted in a biologically inactive (latent) form associated in a non-covalent complex with the ECM. In response to injury, local latent TGF-beta complexes are converted into active TGF-beta according to a tissue- and injury type-specific activation mechanism. Such a well and tightly orchestrated regulation in TGF-beta activity enables an immediate, highly localized response to type-specific tissue injury. In the pathological process of liver fibrosis, TGF-beta plays as a master profibrogenic cytokine in promoting activation and myofibroblastic differentiation of hepatic stellate cells, a central event in liver fibrogenesis. Continuous and/or persistent TGF-beta signaling induces sustained production of ECM components and of tissue inhibitor of metalloproteinase synthesis. Therefore, the regulation of locally activated TGF-beta levels is increasingly recognized as a therapeutic target for liver fibrogenesis. This review summarizes our present knowledge of the activation mechanisms and bioavailability of latent TGF-beta in biological and pathological processes in the liver.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据